BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34252720)

  • 21. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
    Konstantinidis IT; Groot Koerkamp B; Do RK; Gönen M; Fong Y; Allen PJ; D'Angelica MI; Kingham TP; DeMatteo RP; Klimstra DS; Kemeny NE; Jarnagin WR
    Cancer; 2016 Mar; 122(5):758-65. PubMed ID: 26695839
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
    Cercek A; D'Angelica M; Power D; Capanu M; Gewirtz A; Patel D; Allen P; Fong Y; DeMatteo RP; Jarnagin WR; Kemeny NE
    Ann Surg Oncol; 2014 Feb; 21(2):479-86. PubMed ID: 24154839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
    Holster JJ; El Hassnaoui M; Franssen S; IJzermans JNM; de Jonge J; Mostert B; Polak WG; de Wilde RF; Homs MYV; Groot Koerkamp B
    Ann Surg Oncol; 2022 Sep; 29(9):5528-5538. PubMed ID: 35294656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial.
    Kloeckner R; Ruckes C; Kronfeld K; Wörns MA; Weinmann A; Galle PR; Lang H; Otto G; Eichhorn W; Schreckenberger M; Dueber C; Pitton MB
    Trials; 2014 Aug; 15():311. PubMed ID: 25095718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes.
    Kim JH; Yoon HK; Sung KB; Ko GY; Gwon DI; Shin JH; Song HY
    Cancer; 2008 Oct; 113(7):1614-22. PubMed ID: 18704990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Locoregional Therapies of Cholangiocarcinoma.
    Sommer CM; Kauczor HU; Pereira PL
    Visc Med; 2016 Dec; 32(6):414-420. PubMed ID: 28229076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study.
    White J; Carolan-Rees G; Dale M; Patrick HE; See TC; Bell JK; Manas DM; Crellin A; Slevin NJ; Sharma RA
    J Vasc Interv Radiol; 2019 Aug; 30(8):1185-1192. PubMed ID: 31255499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors affecting outcomes of Yttrium-90 radioembolization in heavily pretreated patients with intrahepatic cholangiocarcinoma.
    Zhao K; Erinjeri JP; Sotirchos VS; Alexander ES; Moussa AM; Marinelli B; Ziv E; Sofocleous CT; Abou-Alfa GK; Jarnagin WR; Karimi A; Yarmohammadi H
    Abdom Radiol (NY); 2023 Jul; 48(7):2434-2442. PubMed ID: 37145313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Locoregional therapy combined with systemic therapy (LRT + ST) for unresectable and metastatic intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
    Zhang M; Qi W; Qiu X; Yu C; Qiu W; Wang S; Qiu Z
    Radiol Oncol; 2023 Dec; 57(4):419-429. PubMed ID: 38038416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Transarterial Chemoembolization for Patients with Intrahepatic Cholangiocarcinoma after Surgical Resection: A Systematic Review and Meta-analysis.
    Wang L; Wen X; Zhuang L; Fang K; Shen J
    J Gastrointestin Liver Dis; 2022 Jun; 31(2):215-222. PubMed ID: 35574621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
    Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
    J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma.
    Riby D; Mazzotta AD; Bergeat D; Verdure L; Sulpice L; Bourien H; Lièvre A; Rolland Y; Garin E; Boudjema K; Edeline J
    Ann Surg Oncol; 2020 Oct; 27(10):3729-3737. PubMed ID: 32472411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of postoperative adjuvant transarterial chemoembolization on the prognosis of early-stage intrahepatic cholangiocarcinoma: a single center study.
    Liu G; Guo W; Wang H; Liu W; Lei L; Xie Q; Li X; Zou S; Wang P; Zhou H; Hu H
    Ann Palliat Med; 2021 Apr; 10(4):3673-3683. PubMed ID: 33691434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study.
    Bargellini I; Mosconi C; Pizzi G; Lorenzoni G; Vivaldi C; Cappelli A; Vallati GE; Boni G; Cappelli F; Paladini A; Sciuto R; Masi G; Golfieri R; Cioni R
    Cardiovasc Intervent Radiol; 2020 Sep; 43(9):1305-1314. PubMed ID: 32642986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
    Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transarterial chemoembolization plus lenvatinib with or without a PD-1 inhibitor for advanced and metastatic intrahepatic cholangiocarcinoma: a retrospective real-world study.
    Ning Z; Xie L; Yan X; Hua Y; Shi W; Lin J; Xu L; Meng Z
    Br J Radiol; 2023 Oct; 96(1150):20230079. PubMed ID: 37660471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interventional Oncology: Optimizing Transarterial Therapies for the Treatment of Hepatic Malignancy.
    Kouri BE
    Tech Vasc Interv Radiol; 2018 Dec; 21(4):205-222. PubMed ID: 30545499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.